Seattle Genetics discontinuing lintuzumab

Seattle Genetics Inc. (NASDAQ:SGEN) discontinued development of lintuzumab after the mAb against CD33 missed the primary endpoint in a Phase IIb trial to treat acute myelogenous leukemia (AML). Lintuzumab ( SGN-33) plus low-dose cytarabine did not significantly improve overall survival vs. placebo plus cytarabine. The company said it plans to fulfill its commitments to support an ongoing investigator-sponsored Phase II trial evaluating lintuzumab to treat myelodysplastic syndromes (MDS), but will completely discontinue its development program for lintuzumab to focus on its lead compound, brentuximab vedotin ( SGN-35). ...